GlassScriptPhysician profile
Steven G Scheufler
NPI 1528044799
$7,119.61
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,576 · 2021: $1,695 · 2022: $1,385 · 2023: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $971.01 | 2020-2023 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $919.38 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $893.85 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $443.27 | 2019-2023 | |
| Glaxosmithkline, LLC. | $441.09 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $386.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.39 | 2019-2023 | Spiriva Respimat, Jardiance |
| Amarin Pharma, INC. | $252.45 | 2019-2021 | |
| Allergan, INC. | $236.01 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $201.93 | 2019-2022 | |
| Amgen INC. | $193.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $191.16 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxelis |
| Biohaven Pharmaceuticals, INC. | $181.55 | 2021 | |
| Lilly USA, LLC | $175.77 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $149.92 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.95 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.64 | 2021-2023 | |
| Sanofi Pasteur INC. | $109.06 | 2019-2023 | |
| Optinose US, INC. | $96.96 | 2021 | |
| Gilead Sciences, INC. | $95.18 | 2019-2021 | |
| Astellas Pharma US INC | $86.84 | 2020-2023 | Veozah, Myrbetriq |
| Corcept Therapeutics | $62.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.86 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $48.02 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $40.91 | 2023 | Gemtesa |
| Eisai INC. | $39.88 | 2020 | |
| Almatica Pharma LLC | $30.55 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.36 | 2019-2020 | |
| Dexcom, INC. | $17.76 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $15.33 | 2019 | |
| Hologic Sales and Service, LLC | $15.30 | 2021 | |
| Esperion Therapeutics, INC. | $13.67 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Scheufler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.